Business
Marizyme, Inc. Issues Letter to Shareholders
Marizyme, Inc. Issues Letter to Shareholders.
About this update from Marizyme, Inc.
[{"type":"text","content":"\n\n\n\nMarizyme, Inc. Issues Letter to Shareholders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMarizyme, Inc. Issues Letter to Shareholders\nPR Newswire\nJUPITER, Fla., March 31, 2021\n\n\n\nJUPITER, Fla., March 31, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, and other surgical indications, announces that Board Chairman James Sapirstein has issued a Letter to Shareholders providing a business update for the Company's recent activities. The full text of the Letter, which has also been posted to the Company's website, is as follows:\n\n \n \n \n \n \n \n\n \nDear Fellow Shareholders:\nThis is our first shareholder letter in a while and our Board of Directors and I desired to communicate numerous corporate updates. First and foremost, Neil Campbell has resigned as CEO for good reason, and I have stepped in as interim CEO until we recruit a suitable replacement.  We have begun our search.  However, this has not slowed us down as we continue embarking on new sales opportunities for DuraGraft® in several European countries as well as moving forward with our plans to seek clearance for DuraGraft in the United States.\nCurrently, DuraGraft has been authorized in 33 countries worldwide on four continents, and we have eight distributors covering eight countries, and we are adding more distributors each month with several in the final stages of due diligence before signing agreements.\nWe are working with our current distributor network to increase sales of DuraGraft in our current countries in the EU, South America, Turkey, Chile, and the Southeast Pacific region. The plan is to capitalize on the massive data from our EU Registry study of nearly 3,000 patients to show outcomes and the value of DuraGraft in select patient populations. This includes patients who have diabetes undergoing bypass surgery and those patients whose surgeon uses Endoscopic Vein Graph Harvesting (EVH) approach to support the utilization of fir...